Association of COVID-19 vaccination with risks of hospitalization due to cardiovascular and other diseases: A study of the UK Biobank

Yong XIANG¹, Yaning FENG¹, Jinghong QIU¹, Hon-Cheong SO^{1-7*}

¹School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong

² KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common Diseases, Kunming Institute of Zoology and The Chinese University of Hong Kong, China

³CUHK Shenzhen Research Institute, Shenzhen, China

⁴Department of Psychiatry, The Chinese University of Hong Kong, Shatin, Hong Kong

⁵Margaret K.L. Cheung Research Centre for Management of Parkinsonism, The Chinese University of Hong Kong, Shatin, Hong Kong

⁶Brain and Mind Institute, The Chinese University of Hong Kong, Shatin, Hong Kong

⁷Hong Kong Branch of the Chinese Academy of Sciences Center for Excellence in Animal Evolution and Genetics, The Chinese University of Hong Kong, Hong Kong SAR, China

**Corresponding author*

Correspondence to: Hon-Cheong So, MBBS, PhD. Lo Kwee-Seong Integrated Biomedical Sciences Building, The Chinese University of Hong Kong, Shatin, Hong Kong. Tel: +852 3943 9255; E-mail: hcsso@cuhk.edu.hk

Submitted on 5 Nov 2021

Abstract

Background Vaccines for COVID-19 represent a breakthrough in the fight against the pandemic. However, worries about adverse effects led to vaccine hesitancy in some people. On the other hand, as COVID-19 may be associated with various sequelae, the vaccine may protect against these diseases.

Methods We leveraged a large prospective cohort, the UK-Biobank(UKBB), and studied associations of at least one dose of COVID-19 vaccination(BioNTech-BNT162b2 or Oxford-AstraZeneca-ChAdOx1) with hospitalization from cardiovascular and other diseases ($N=393,544$; median follow-up of 54 days in vaccinated). Multivariable Cox and Poisson regression was conducted controlling for main confounders. Besides all hospitalizations, we also conducted separate analysis for new-onset and recurrent cases. We also performed other sensitivity analyses, including adjustment for prior event rate ratio (PERR) to reduce residual confounding.

Results We observed that COVID-19 vaccination(at least one dose) was associated with lower risks of hospitalizations from stroke (hazard ratio[HR]=0.178, 95% CI: 0.127-0.250, $p=1.50e-23$), VTE (HR=0.426, 95% CI: 0.270-0.673, $p=2.51e-4$), dementia (HR=0.114, 95% CI 0.060-0.216; $p=2.24e-11$), non-COVID-19 pneumonia (NCP) (HR=0.108, 95% CI 0.080-0.145; $p=2.20e-49$), CAD (HR=0.563, 95% CI: 0.416-0.762; $p=2.05e-4$), COPD (HR=0.212, 95% CI 0.126-0.357; $p=4.92e-9$), T2DM (HR= 0.216, 95% CI: 0.096 - 0.486, $p=2.12e-4$), heart failure (HR=0.174, 95% CI, 0.118-0.256, $p=1.34e-18$) and renal failure (HR=0.415, 0.255- 0.677, $p=4.19e-4$).

After adjusting for HRs of hospitalization between the two groups *before* the introduction of vaccination, COVID-19 vaccination was still significantly associated with reduced hazards of hospitalization due to CAD (HR=0.517, 95% CI: 0.327-0.817; $p=4.70e-03$), COPD (HR=0.317, 95% CI: 0.138-0.726; $p=6.60e-03$), dementia (HR=0.406, 95% CI: 0.180-0.919; $p=3.06e-02$), heart failure (HR=0.305, 95% CI: 0.179-0.519; $p=1.18e-05$), NCP (HR=0.191, 95% CI: 0.123-0.295; $p=1.02e-13$) and stroke (HR=0.222, 95% CI: 0.130-0.382; $p=4.94e-08$), although the estimated protective effects were weaker.

Conclusions Taken together, this study provides further support to the safety and benefits of COVID-19 vaccination, and such benefits may extend beyond reduction of infection risk or severity per se. As an observational study, causal relationship cannot be concluded and further studies are required to verify the findings.

Introduction

More than 245 million confirmed cases of COVID-19 and >4.9 million fatalities have been reported as at 29 Oct 2021. Vaccines for COVID-19 have been developed at an unprecedented speed, and offer hope to reduce the burden of this pandemic. Nevertheless, vaccine hesitancy has been a major hurdle, and some may worry about adverse effects or exacerbation of existing diseases^{1,2}. There have been case reports of fatalities after vaccination^{3,4}, which has led to concerns about the safety of the vaccine among some people. However, so far there has been no direct evidence that COVID-19 vaccination is causally linked to increased risks of mortality in general.

On the other hand, as COVID-19 may be associated with a range of complications such as cardiovascular/cerebrovascular events, thromboembolism, renal failure etc.^{5,6}, it is reasonable to hypothesize that COVID-19 vaccination may reduce the risks of these complications. Of note, it has been shown in many reports and meta-analysis that influenza vaccination is associated with reduced cardiovascular risks. For example, a recent meta-analysis of both randomized controlled trials and observational studies⁷ showed that flu vaccination was associated with a lower risk of all-cause and cardiovascular (CV) mortality, as well as major CV events compared to controls. Other meta-analysis also reported similar findings of reduced CV and stroke risks⁸⁻¹⁰. Although reduction of flu infection is a possible mechanism, it has also been reported that flu vaccines may promote plaque stabilization via its interaction with the immune system^{11,12}. Other mechanism such as increased nitric oxide production has been proposed¹³. In view of these findings, it is possible that COVID-19 vaccination may also reduce cardiovascular risks and risks from other diseases.

Here we conducted a study to investigate the association of COVID-19 vaccination with hospitalization from cardiovascular and other diseases. Cardiovascular diseases (CVD) are chosen for analysis as they are leading cause of mortalities worldwide, and the protective effects of flu vaccines against CVD lead us to hypothesize that similar effects may also be observed for COVID-19 vaccines. Besides CVD, we also included in our analyses several other diseases that are likely linked to COVID-19 as complications/sequelae. For example, renal dysfunction is a common complication of the infection¹⁴ and is closely related to CVD. COPD exacerbation is common after viral infections¹⁵ and is likely to be a relevant complication. Venous thromboembolism (VTE) is also one of the major complications of COVID-19¹⁶. In addition, both the infection and vaccination involve complex interplay with the immune system, and therefore related disorders such as autoimmune diseases may be associated with the infection and/or vaccination¹⁷. As for neurological sequelae, a recent study revealed that across all neuropsychiatric disorders, the risks of mortality from dementia appeared to be particularly elevated¹⁸. In this work, the association of COVID-19 vaccination with hospitalization from the above diseases will be investigated.

Methods

UK Biobank sample

The UK Biobank (UKBB) is a large-scale prospective cohort comprising ~500,000 subjects aged 40–69 years when they were recruited in 2006–2010. The current age of subjects included in our analyses ranged from 50 to 87 years. For details of the UK Biobank cohort please also refer to¹⁹. We included subjects with vaccination records from General Practice (GP) records under the TPP and EMIS systems (sample size $N=393,544$). The present analysis was conducted under the project number 28732.

Outcome definition

Hospitalization records were extracted from the Hospital Episode Statistics (HES) of UKBB. Detailed descriptions of the HES can be found in <https://biobank.ndph.ox.ac.uk/ukb/ukb/docs/HospitalEpisodeStatistics.pdf>. The inpatient core and diagnoses datasets were updated to 31 Mar 2021. The diagnosis codes and corresponding dates were summarized based on each participant's inpatient record. All the diagnosis codes were converted to 3-character ICD-10 codes. We followed the mapping strategy as described in https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/first_occurrences_outcomes.pdf.

The ICD codes for defining each disease outcome were listed in Table S1. The disease outcomes (hospitalization) studied included coronary artery disease (CAD), atrial fibrillation (AF), heart failure (HF), hypertension (HTN), stroke, renal failure (RF), type 2 diabetes mellitus (T2DM), venous thromboembolism (VTE), immunodeficiencies, systemic and organ-specific autoimmune diseases, chronic obstructive pulmonary disease (COPD), non-COVID-19 pneumonia (NCP) and dementia.

Only primary causes of admission were considered. All diagnosis given before the date of first vaccination were regarded as medical history of comorbidities; diagnoses given after the date of first vaccination were treated as new hospitalization. For better statistical power, we primarily present the results from any hospitalizations from the studied diseases. However, we also conducted further stratified analysis on new-onset (subjects with no prior history) and recurrent/relapse diseases (subjects with known history of the disease).

Covariates

The full set of covariates included basic demographic variables (age, sex, ethnic group), comorbidities (CAD, stroke, T2DM, HTN, AF, COPD, dementia, history of cancer, chronic kidney disease[CKD], history of pneumonia), risk factors of cardiometabolic disorders (lipids, glucose levels, HbA1c), disorders of the immune system (autoimmune diseases, immunodeficiency, drug history of immunosuppressants), indicators of general health (number of medications prescribed by GP in the past year, number of hospitalizations in the past year, number of non-cancer illnesses), anthropometric/obesity measures (body mass index [BMI], waist circumference), socioeconomic status (Townsend Deprivation index) and lifestyle risk factor (smoking status). For disease traits, we included information from primary care data, hospital inpatient data, ICD-10 diagnoses (code 41270), and self-reported illnesses (code 20002) and incorporated data from all waves of follow-ups. The strategy of integrating all the diagnosis records were based on information

provided by UKBB (https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/first_occurrences_outcomes.pdf). Subjects with no records of the relevant disease from any data source were regarded as having no history of the disease. Covariates were selected based on potential relevance to COVID-19 and/or its complications, based on literature evidence. The full list of covariates is listed in Table S2.

We note that the number of events may be small for some diseases, yet the number of covariates is relatively large. In view of this, we performed regression analyses using two strategies: (1) ‘Basic’ model: the basic model includes age, sex, prior infection, number of hospitalizations and number of medications received in the past year as covariates; (2) ‘advanced’ model: under this strategy, all covariates were considered. We first included the covariates under the basic model. For the rest of the covariates, we first performed univariate screening test with each covariate; those with (nominally) significant association ($p < 0.05$) with the hospitalization outcome would be selected into the final model. This approach followed the methodology described by Zhao et al.²⁰, which has been shown by theory and simulations to control the proportion of false positive predictors.

Missing covariate data

Missing values of remaining features were imputed with the R package missRanger. The program is based on missForest, which is an iterative imputation approach based on random forest. It has been widely used and has been shown to produce low imputation errors and good performance in predictive models²¹. The missing rate of each covariate and the OOB (out-of-bag error) of the one-time imputation were listed in Table S3.

COVID-19 infection status

COVID-19 testing data were downloaded from the UKBB data portal. Information regarding COVID-19 data in the UKBB was given at <https://biobank.ndph.ox.ac.uk/showcase/exinfo.cgi?src=COVID19>. Briefly, the latest COVID test results were downloaded from UKBB with last update on 21 Jul 2021. Diagnosis of COVID-19 (ICD code: U071) from hospital inpatient or mortality records were also extracted. Subjects with any positive testing results, diagnosis of COVID-19 (U071) from health records or the “Y2a3b” code within TPP clinical records (<https://biobank.ndph.ox.ac.uk/showcase/coding.cgi?id=8708&nl=1>) during the follow-up period were regarded as having a history of COVID-19 infection. Untested subjects or subjects without any positive results were treated as uninfected.

Vaccination status definition

Vaccination status was extracted from the TPP and EMIS General Practice clinical records (TPP last update 21 Jul 2021; EMIS last update 10 Aug 2021). Since the type of vaccine was not recorded for most subjects, we did not stratify our analysis based on vaccine type. During the period of study, all subjects received either the BioNTech BNT162b2 or Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine. Also, since few events were observed within fully vaccinated (i.e., vaccinated with two doses) subjects at the time of analysis, we consider vaccination with at least one dose of COVID-19 vaccine as the main exposure.

Statistical analysis

Two types of regression models were employed, namely Cox and Poisson regression. Cox regression models time to development of event, while Poisson regression models the incidence rate (with consideration of follow-up time). Briefly,

the time to hospitalization from the studied diseases was treated as outcome in Cox regression, controlling for other covariates. We performed check of the proportional hazards (PH) assumption by testing if the Schoenfeld residuals are independent of time using the R function `cox.zph`. For Poisson regression, presence/absence of the event of interest was considered as outcome, with ‘offset’ specified (=number of days of follow-up) to account for the differences in duration of follow-up for each subject. For vaccinated subjects, the start-date was set at the date of first vaccination; for unvaccinated subjects, the start-date was set at 8 Dec 2020, the date COVID-19 vaccines were first deployed in the UK. The end of follow-up was set at 31 Mar 2021 for outcomes related to hospitalization, as UKBB records were updated up to these dates at the time of analysis. All statistical analysis were performed by R (version number 3.6.1).

Prior event rate ratio (PERR) adjustment

Although we have adjusted for many covariates, the chance of residual confounding remains. The PERR approach is a useful methodology to minimize the effect of unmeasured confounders²²⁻²⁴. The basic idea is to adjust for the differences in event rates between the two (treated and untreated) groups before the initiation of treatment, such that baseline differences between the two groups can be accounted for.

In brief, let us assume that *before* the initiation of vaccination program, the hazard ratio of event (e.g. hospitalization due to stroke) between the vaccinated and unvaccinated groups is HR_{before} . Since neither groups have actually received the vaccination during this period, HR_{before} is assumed to reflect baseline differences due to effects of unmeasured confounders. Similarly, we define the HR of event between the vaccinated and unvaccinated groups *after* the initiation of vaccination program to be HR_{after} . The PERR-adjusted HR, calculated as $HR_{\text{after}}/HR_{\text{before}}$, provides an estimate of the treatment effect accounting for both unmeasured and measured confounders. The evaluation of $HR_{\text{after}}/HR_{\text{before}}$ is equivalent to evaluating the difference in regression coefficients before and after treatment, i.e. $\beta_{\text{diff}} = \beta_{\text{after}} - \beta_{\text{before}}$. Since the covariance of β_{after} and β_{before} cannot be easily derived, a bootstrap procedure was used to estimate the standard error (SE) of β_{diff} ²². The z-statistic is derived from $\beta_{\text{diff}}/SE(\beta_{\text{diff}})$. One thousand bootstraps were performed.

The PERR approach have several assumptions. It is assumed that the confounders (measured and unmeasured) have the same effect in both pre- and post-treatment periods. Also, treatment allocation is assumed to be unaffected by events in the prior period (in this case, it is assumed that previous hospitalization due to the studied diseases did not affect the probability of receiving vaccination).

Prescription-time distribution matching (PTDM)

For the vaccinated group, a person needs to survive until the date he/she receives vaccination, which can introduce a type of bias known as ‘survival bias’. Individuals who die shortly after the start of follow-up will not have the opportunity to receive vaccination, and this can result in a survival advantage for the treated (vaccinated) subjects. This bias will be most substantial if mortality is considered as the outcome. Note that in our case, we focused on hospitalization as the outcome, so the effect of survival bias may not be as severe. A person can still get vaccinated after being hospitalized for a disease; however, hospitalization is a risk factor of mortality, hence some degree of survival bias may still be present.

Several methods have been proposed to correct for such bias²⁵. Here we employed the PTDM approach as it is relatively easy to implement and computationally fast, and has been shown to effectively reduce survival bias²⁵. In brief, for each unvaccinated person, instead of setting time0 at the same date (8 Dec 2020; earliest date of vaccination), the start-date (time0) is randomly chosen from the start-dates of the vaccinated group. The objective is to ensure a similar distribution of the start-dates (time0) across both groups. Since the start-dates of the unvaccinated group will be pushed to later dates, the number of events in the unvaccinated will be reduced under the PTDM approach, which may lead to less precise estimates and a loss of power. In our case where only a subset of patients is subject to survival bias (only a subgroup of hospitalized patients will succumb to the disease, hence unable to receive vaccination), this adjustment may be conservative.

Other analysis to check for robustness of findings

We performed a variety of other analyses to verify the robustness of our findings under different modeling strategies and assumptions: (1) While we primarily focused on all hospitalizations/fatalities regardless of past history of the disease, we also conduct stratified analysis for new-onset and recurrent diseases, as described above; (2) for counting the ‘start-date’, we primarily consider day 0 as the day of vaccination, as it is possible that some side-effects can occur early. However, we also performed another set of analysis with start-date set at 14 days after the 1st vaccination, since the protective effects of vaccines may only be apparent ~2 weeks later; (3) we also repeated the analyses limited to those with no recorded history of infection all along. Note that as UKBB subjects were not routinely screened for infection, a substantial proportion of asymptomatic and milder infections might not be captured. This analysis may reveal whether vaccination may confer protective effects against other diseases presumably via protection against milder infections.

Results

We will primarily present our findings with at least one dose of vaccination, and results from Cox regression with start-date defined as the day of (first) vaccination. We will then also present the results with PERR and PTDM adjustment. If not further specified, we will describe the results under the ‘advanced’ model (which considers the full set of covariates), although the results from basic and advanced models were generally similar. As described below and in supplementary information, the main findings are mostly robust to different modeling strategies. The results from Cox and Poisson regression models were highly similar, with comparable sets of significant associations. The full results of all analyses are presented in Tables S4 to S9. The median length of follow-up in the vaccinated group was 54 days, and the corresponding length was 113 days in the unvaccinated group without PTDM adjustment and 55 days with PTDM.

Association of hospitalization with COVID-19 vaccination status (at least one dose of vaccine)

The main results are listed in Table 1 and full results in Tables S4 to S5. Please also refer to Figure 1. Here we first present the results based on Cox regression model (‘advanced’ model with consideration of all covariates and pre-screening), without further adjustments by PTDM or PERR. Considering all hospitalizations (regardless of history of the studied disease), COVID-19 vaccination was significantly associated with reduced hazards of hospitalization due to stroke (hazard ratio [HR]=0.178, 95% CI: 0.127-0.250, $p=1.50e-23$), VTE (HR=0.426, 95% CI: 0.270-0.673, $p=2.51e-4$),

dementia (HR=0.114, 95% CI 0.060-0.216; $p=2.24e-11$), non-COVID-19 pneumonia (NCP) (HR=0.108, 95% CI 0.080-0.145; $p=2.20e-49$), CAD (HR=0.563, 95% CI: 0.416-0.762; $p=2.05e-4$), COPD (HR=0.212, 95% CI 0.126-0.357; $p=4.92e-9$), T2DM (HR= 0.216, 95% CI: 0.096 - 0.486, $p=2.12e-4$), heart failure (HR=0.174, 95% CI, 0.118-0.256, $p=1.34e-18$) and renal failure (HR=0.415, 0.255- 0.677, $p=4.19e-4$). The results from the ‘basic’ regression model (with less covariates included) were similar, with slightly lower HR estimates (i.e. stronger protective associations) (Table S7).

Restricting the outcome to hospitalizations due to *new-onset* diseases (i.e. without prior history), we observed that vaccination was associated with reduced hazards of hospitalizations from stroke (HR=0.219, 95% CI: 0.147-0.325; $p=8.40e-3$), renal failure (HR=0.181, 95% CI: 0.080-0.411; $p=4.36e-5$), heart failure (HR=0.255, 95% CI: 0.131-0.498; $p=6.08e-5$), VTE (HR=0.481, 95% CI: 0.279-0.829; $p=8.40e-3$), dementia (HR=0.189, 95% CI: 0.047-0.764; $p=1.94e-2$) and NCP (HR=0.090, 95% CI 0.061-0.131; $p=9.88e-36$). Note that the number of events was too small for further analyses for some diseases. There were only 5 and 8 new hospitalizations due to dementia in the unvaccinated and vaccinated groups, so the results should be viewed with caution.

On the other hand, if we consider hospitalizations due to *recurrent* disease (i.e. those with known history of the disease) as outcome, vaccination was associated with decreased hospitalization hazards due to stroke (HR=0.096, 95% CI: 0.050-0.183; $p=2.04e-3$), CAD (HR=0.483, 95% CI: 0.330-0.705; $p=1.68e-4$), COPD (HR=0.221, 95% CI: 0.129-0.381; $p=5.40e-8$), heart failure (HR=0.145, 95% CI: 0.089-0.236; $p=9.82e-15$), NCP (HR=0.141, 95% CI: 0.088-0.225), VTE (HR=0.369, CI:0.156-0.874, $p=2.35e-2$) and dementia (HR=0.058, CI:0.028-0.118; $p=5.82e-15$). In general, the protective associations were more prominent in recurrent cases when compared to all hospitalizations without consideration of disease history.

The results from the ‘basic’ regression models for hospitalizations due to new or recurrent disease were similar, with slightly lower HR estimates (Table S7). The same set of significant associations were observed. For completeness, we also present the results when all covariates were included without pre-screening (Table S8). We show by default only the results without warnings of convergence issues from the “coxph” function.

We also repeated the analysis using Poisson regression which models the incidence rate of hospitalization. The results were highly similar to those from Cox regression, with similar significant associations observed (Tables S4-5).

With PERR adjustment to reduce residual confounding

The primary results with PERR adjustment (number of bootstraps=1000; the prior-to-vaccination period restricted to 1-Jan-2019 to 7-Dec-2020) are listed in Table 2 and Table S6. After PERR adjustment, COVID-19 vaccination was significantly associated with reduced hazards of hospitalization due to CAD (HR=0.517, 95% CI: 0.327-0.817; $p=4.70e-03$), COPD (HR=0.317, 95% CI: 0.138-0.726; $p=6.60e-03$), dementia (HR=0.406, 95% CI: 0.180-0.919; $p=3.06e-02$), heart failure (HR=0.305, 95% CI: 0.179-0.519; $p=1.18e-05$), NCP (HR=0.191, 95% CI: 0.123-0.295; $p=1.02e-13$) and stroke (HR=0.222, 95% CI: 0.130-0.382; $p=4.94e-08$).

Additionally, we performed PERR with two other one-year ‘prior’ periods (1-Jan-2019 to 7-Dec-2019 and 8-Dec-2019 to 7-Dec-2020 respectively); the results were largely similar. Full results are shown in Table S6. Due to high computational cost, we performed PERR analysis only for the advanced model with covariate selection.

Other sensitivity analyses

PTDM adjustment The main results with PTDM adjustment are presented in Table 3. Under PTDM adjustment (no PERR), reduced hazards of hospitalization were observed for dementia (HR=0.182, 95% CI: 0.072-0.461; $p=3.21e-04$), heart failure (HR=0.175, 95% CI: 0.107-0.286; $p=3.88e-12$), NCP (HR=0.158, 95% CI: 0.107-0.234; $p=3.14e-20$), stroke (HR=0.284, 95% CI: 0.177-0.456; $p=1.92e-07$) and T2DM (HR=0.308, 95% CI: 0.102-0.935; $p=3.77e-02$). As discussed earlier, the PTDM approach may tend to be conservative in this study which focused on hospitalization (instead of mortality) as the outcome. This purpose of the adjustment is to provide an extra sensitivity analysis to examine the robustness of findings.

Different start-dates We also repeated all our analyses (hospitalization as outcome) with the start-date defined as 14 days after (first) vaccination, as the vaccine may take longer to exert protective effects for infection. The results were largely similar to the above and are shown in Tables S4-5. Significant findings were similar to the primary analyses.

Subjects with no known infection In another secondary analysis, we limited our analysis to subjects with no known history of COVID-19 infection all along. Here we present the results with PERR adjustment (prior period set to 1-Jan-2019 to 7-Dec-2020), which controls for residual confounding. We observed reduced hospitalization hazards from CAD (HR=0.663, 95% CI: 0.447-0.982, $p=4.04e-02$), COPD (HR=0.465, 95% CI: 0.246-0.877, $p=1.80e-02$), heart failure (HR=0.502, 95% CI: 0.324-0.778, $p=2.05e-03$), NCP (HR=0.290, 95% CI: 0.201-0.420, $p=5.24e-11$) and stroke (HR=0.321, 95% CI: 0.203-0.508, $p=1.20e-06$) (Table S4-5). There was no significant association of vaccination with dementia. The HR estimates were higher (but all $HR<1$) when restricted to subjects with no known infection, indicating weaker protective associations.

As for tests of the proportional hazards assumption, there was no evidence of violation of the proportional hazards (PH) assumption for the majority of Cox regression results (all $p>0.05$, Table S9).

Discussions

Overview of main findings

Overall, we observed that COVID-19 vaccinations (at least one dose) was associated with lower risks of hospitalizations from several diseases in short-term follow-up. In particular, reduced hospitalizations for stroke, heart failure, NCP and dementia were consistently observed across different analyses, including after the PERR adjustment. Reduced hazards of hospitalization was also observed for CAD and COPD, which remained significant after adjustment for prior event rates. We also observed decreased hospitalizations risks for VTE, renal failure and T2DM in our analyses, which may be worthy of further investigations, although the associations were not significant after PERR adjustment. In general, there is no evidence that vaccination was associated with increased hospitalization from the disorders studied here, providing further support for the general safety of the vaccines.

Interpretation of findings

There is unequivocal evidence that both the BioNTech and Oxford-AstraZeneca vaccines were effective in reducing the risks of COVID-19 infection and severe disease, and partially vaccinated individuals are also protected, especially against severe disease^{26,27}. There has also been mounting evidence that COVID-19 is associated a range of sequelae^{28,29}. For instance, previous studies showed that COVID-19 was associated with elevated risks of stroke^{30,31}, VTE¹⁶, heart failure³² and other cardiac disorders³³, renal dysfunction³⁴, bacterial pneumonia³⁵ and mortality associated with dementia¹⁸. COVID-19 is also associated with higher cardiovascular and all-cause mortality, up to 6 months after the infection²⁹. Taken together, COVID-19 vaccines may partially protect against hospitalization from some of the above disorders, possibly via reducing risks of infection and severe disease. An analogy may also be drawn with influenza vaccinations. As also described in the introduction section, a number of studies have shown that flu vaccination was associated with reduced cardiovascular risks and mortality, despite that flu vaccines in general have lower efficacy and the risks of severe disease and complications from flu are lower than those from COVID-19.

A recent nation-wide study³⁶ examined the safety and potential adverse effects of the BNT162b2 vaccine with a follow-up period of ~42 days. Considering adverse effects, the largest effect size was observed for myocarditis (HR=3.24, 95% CI : 1.55 – 12.44), although COVID-19 itself was associated with a much higher risk of myocarditis (HR=18.28, 95% CI 3.95 – 25.12). We did not cover myocarditis here due to low incidence of the condition. Although not the primary focus of the study, the authors also reported significantly reduced incidence of several conditions, including acute kidney injury, anemia, intracranial hemorrhage and other thrombosis³⁶. We also observed reduced hazards of renal failure, VTE and stroke hospitalizations after vaccination in this study, corroborating with previous findings.

Interestingly, we observed that the protective associations for several diseases (including CAD, COPD, heart failure, NCP and stroke) remained after restriction to subjects with no known history of infection all along, although the effect sizes were attenuated. We speculate that one possible explanation is that subjects with mild or moderate infections may not get tested, but such infections can still be associated with elevated risks of complications compared to the non-infected population²⁹. COVID-19 vaccination also protects against mild and even asymptomatic infections^{27,37} and hence may also protect against the corresponding complications. An alternative possibility is that the vaccine may also provide beneficial effects via other mechanisms beyond protection from COVID-19 infection. For flu vaccine, pre-clinical studies have shown that it may stabilize atherosclerotic plaques and lead to increased nitric oxide production¹². However, the exact mechanisms still require further investigations. Of note, some previous studies have shown that vaccines may confer non-specific protection against diseases not originally targeted by them. For example, several studies have shown potential benefits of flu vaccines against infection or severe infection from COVID-19³⁸⁻⁴⁰, and there is evidence that other vaccines such as MMR or BCG may protect against COVID-19⁴¹⁻⁴³ through ‘training’ of innate immunity. One may speculate that COVID-19 vaccines may also confer some non-specific protective effects against other respiratory infections such as other types of pneumonia.

Strengths and limitations

This study is based on a relatively large sample with detailed phenotypic information and health records. We have conducted a comprehensive analysis covering a wide range of cardiovascular and other relevant diseases. We have also

conducted analyses under different statistical models to evaluate if the findings are robust to different modeling strategies. For example, the PERR method adjusts for the HR before the introduction of vaccines, in order to minimize residual confounding.

There are several limitations of the present study. First and foremost, this is a real-world observational study without randomization of vaccination. As such, residual confounding cannot be excluded, and our results should not be regarded as confirmatory evidence of causal relationships between vaccination and the diseases under study. We have controlled for a wide range of covariates such as general health and comorbidities, but residual confounding may still be present. Possible confounders may include, for instance, differences in health consciousness or other health-seeking behaviors between the vaccinated and non-vaccinated groups. We have employed the PERR approach to reduce unmeasured confounding, and it is reassuring that a number of associations remained significant after the adjustment.

Another limitation is that while the total sample size is large, the number of events is still small in view of the short period of follow-up. Also due to relatively short follow-ups, longer-term effects of vaccinations cannot be addressed. A related limitation is that relatively few events were observed in fully vaccinated individuals (and the time for available for follow-up is much shorter), and therefore we decided to focus on the effects of at least one dose of vaccine. Also, studies have showed that vaccine effectiveness in preventing infection may wane over time^{44,45}; it is unknown whether the effect in preventing the diseases studied here will also attenuate over time. However, current evidence suggests that the effectiveness against severe infections remains at satisfactory levels. Another limitation is that we could not retrieve the type of vaccine (BioNTech or Oxford-AstraZeneca) for most subjects; practically, stratified analysis will also further reduce statistical power due to limited number of events. The emergence of viral variants, such as the delta variant, may also affect the efficacy of vaccines⁴⁶ but variant information is currently unavailable in the UKBB. Finally, the UKBB may not be representative of the entire UK population, as participants are generally healthier and of higher socioeconomic status than non-participants⁴⁷. Also, the generalizability of the findings to other types of COVID-19 vaccines and other populations (e.g. different age groups and ethnicities) remains to be studied.

Conclusions

In conclusion, the current study suggests that COVID-19 vaccination may protect against hospitalization from several diseases, such as stroke, heart failure, CAD, NCP, COPD and dementia. Taken together, this study provides further support to the safety and benefits of COVID-19 vaccination, and such benefits may be beyond reduction of infection risk or disease severity per se. As an observational study, causal relationship cannot be concluded and further studies are required to verify the findings.

Figure legends

Figure 1 An overview of association of (at least one dose of) COVID-19 vaccination with hospitalization from various diseases. The analysis was conducted under the ‘advanced model’ with consideration of all covariates and pre-screening, without PTDM or PERR adjustments.

Totally three types of outcomes were defined: hos_after_vaccination, all hospitalizations after vaccination; new-onset, hospitalizations from new-onset diseases (without prior history of the disease); relapse, hospitalizations among those with known history of the studied disease. To avoid unstable estimates from very few events, we present the results only if the number of events ≥ 5 in at both vaccinated and un-vaccinated groups.

Author Contributions

Conception and design: HCS (lead), with input from YX and YF. Study supervision: HCS. Funding acquisition: HCS. Methodology: HCS (lead), YX. Data curation: YX (lead), YF, JQ. Data analysis: YX (lead), YF, JQ. Data interpretation: HCS, YX, YF. Preparation of first draft of manuscript: HCS (lead), YX, with input from YF and JQ.

Acknowledgements

This work was supported partially by a National Natural Science Foundation China (NSFC) grant (81971706) and the Lo Kwee Seong Biomedical Research Fund from The Chinese University of Hong Kong and the KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common Diseases, Kunming Institute of Zoology and The Chinese University of Hong Kong, China. We thank Prof. Pak Sham for support on data access.

Supplementary Information

All supplementary Tables and notes are available at <https://drive.google.com/drive/folders/10bPR8Z8d396gtnO5FAgpILUMsqR6BTqo?usp=sharing>

Conflicts of interest

The authors declare no relevant conflicts of interest.

References

1. Rief, W. Fear of Adverse Effects and COVID-19 Vaccine Hesitancy: Recommendations of the Treatment Expectation Expert Group. *JAMA Health Forum* **2**, e210804-e210804 (2021).
2. DELPHI & Facebook. Topline Report on COVID-19 Vaccination in the United States. in *COVID-19 Symptom Survey* (2021).
3. Torjesen, I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. *BMJ* **372**, n149 (2021).
4. Overview of reports with fatal outcome after COVID-19 vaccination in the first 8 weeks of Dutch vaccination campaign. in *Medicines Evaluation Board* (2021).
5. Leung, T.Y.M. *et al.* Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. *Emerging Microbes & Infections* **9**, 2190-2199 (2020).
6. Pellicori, P. *et al.* COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. *Cochrane Database of Systematic Reviews* (2021).
7. Yedlapati, S.H. *et al.* Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-analysis. *Journal of the American Heart Association* **10**, e019636 (2021).
8. Zangiabadian, M. *et al.* Protective effect of influenza vaccination on cardiovascular diseases: a systematic review and meta-analysis. *Scientific Reports* **10**, 20656 (2020).
9. Udell, J.A. *et al.* Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients: A Meta-analysis. *JAMA* **310**, 1711-1720 (2013).
10. Lee, K.R. *et al.* Effect of Influenza Vaccination on Risk of Stroke: A Systematic Review and Meta-Analysis. *Neuroepidemiology* **48**, 103-110 (2017).
11. Bermúdez-Fajardo, A. & Oviedo-Orta, E. Influenza vaccination promotes stable atherosclerotic plaques in apoE knockout mice. *Atherosclerosis* **217**, 97-105 (2011).
12. Behrouzi, B. *et al.* Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art Review. *Journal of the American College of Cardiology* **76**, 1777-1794 (2020).
13. Veljkovic, V. *et al.* Influenza vaccine as prevention for cardiovascular diseases: possible molecular mechanism. *Vaccine* **32**, 6569-75 (2014).
14. Nadim, M.K. *et al.* COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. *Nature Reviews Nephrology* **16**, 747-764 (2020).
15. Polverino, F. & Kheradmand, F. COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects. *Frontiers in Medicine* **7**(2021).
16. Loo, J., Spittle, D.A. & Newnham, M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. *Thorax* **76**, 412-420 (2021).
17. Liu, Y., Sawalha, A.H. & Lu, Q. COVID-19 and autoimmune diseases. *Curr Opin Rheumatol* **33**, 155-162 (2021).
18. Bhaskaran, K. *et al.* Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: cohort study in OpenSAFELY using linked primary care, secondary care and death registration data. *medRxiv*, 2021.07.16.21260628 (2021).
19. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine* **12**, e1001779-e1001779 (2015).
20. Zhao, S.D. & Li, Y. Principled sure independence screening for Cox models with ultra-high-dimensional covariates. *Journal of Multivariate Analysis* **105**, 397-411 (2012).
21. Waljee, A.K. *et al.* Comparison of imputation methods for missing laboratory data in medicine. *BMJ Open* **3**, e002847 (2013).
22. Weiner, M.G., Xie, D. & Tannen, R.L. Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding. *Pharmacoepidemiol Drug Saf* **17**, 661-70 (2008).
23. Rodgers, L.R. *et al.* Prior event rate ratio adjustment produced estimates consistent with randomized trial: a diabetes case study. *Journal of Clinical Epidemiology* **122**, 78-86 (2020).
24. Uddin, M.J. *et al.* Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study. *Pharmacoepidemiol Drug Saf* **24**, 468-77 (2015).

25. Zhou, Z., Rahme, E., Abrahamowicz, M. & Pilote, L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. *Am J Epidemiol* **162**, 1016-23 (2005).
26. Lopez Bernal, J. *et al.* Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ* **373**, n1088 (2021).
27. Voysey, M. *et al.* Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *The Lancet* **397**, 881-891 (2021).
28. Nalbandian, A. *et al.* Post-acute COVID-19 syndrome. *Nature Medicine* **27**, 601-615 (2021).
29. Al-Aly, Z., Xie, Y. & Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature* **594**, 259-264 (2021).
30. Merkler, A.E. *et al.* Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza. *JAMA Neurology* **77**, 1366-1372 (2020).
31. Fridman, S. *et al.* Stroke risk, phenotypes, and death in COVID-19: Systematic review and newly reported cases. *Neurology* **95**, e3373-e3385 (2020).
32. Italia, L. *et al.* COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae. *Frontiers in Cardiovascular Medicine* **8**(2021).
33. Farshidfar, F., Koleini, N. & Ardehali, H. Cardiovascular complications of COVID-19. *JCI Insight* **6**(2021).
34. Nugent, J. *et al.* Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19. *JAMA Network Open* **4**, e211095-e211095 (2021).
35. Farrell, J.M., Zhao, C.Y., Tarquinio, K.M. & Brown, S.P. Causes and Consequences of COVID-19-Associated Bacterial Infections. *Frontiers in Microbiology* **12**(2021).
36. Barda, N. *et al.* Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *New England Journal of Medicine* **385**, 1078-1090 (2021).
37. Dagan, N. *et al.* BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *New England Journal of Medicine* **384**, 1412-1423 (2021).
38. Xiang, Y., Wong, K.C.-Y. & So, H.-C. Exploring Drugs and Vaccines Associated with Altered Risks and Severity of COVID-19: A UK Biobank Cohort Study of All ATC Level-4 Drug Categories Reveals Repositioning Opportunities. *Pharmaceutics* **13**, 1514 (2021).
39. Conlon, A., Ashur, C., Washer, L., Eagle, K.A. & Hofmann Bowman, M.A. Impact of the influenza vaccine on COVID-19 infection rates and severity. *American Journal of Infection Control* **49**, 694-700 (2021).
40. Pawlowski, C. *et al.* Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations. *medRxiv*, 2020.07.27.20161976 (2020).
41. Mysore, V. *et al.* Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens. *Med* **2**, 1050-1071. e7 (2021).
42. Escobar, L.E., Molina-Cruz, A. & Barillas-Mury, C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). *Proceedings of the National Academy of Sciences* **117**, 17720 (2020).
43. Gonzalez-Perez, M., Sanchez-Tarjuelo, R., Shor, B., Nistal-Villan, E. & Ochando, J. The BCG Vaccine for COVID-19: First Verdict and Future Directions. *Front Immunol* **12**, 632478 (2021).
44. Chemaitelly, H. *et al.* Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *New England Journal of Medicine* (2021).
45. Tartof, S.Y. *et al.* Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *The Lancet* (2021).
46. Puranik, A. *et al.* Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. *medRxiv*, 2021.08.06.21261707 (2021).
47. Fry, A. *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol* **186**, 1026-1034 (2017).

Table 1 Association of (at least one dose of) COVID-19 vaccination with hospitalization from various disorders

Outcome	Coef	Exp(coef) [HR]	SE(coef)	Z	P	LCI	UCI	No of events in unvac	Rate of events in unvac (per 100,000 person-days)	No of events in vac	Rate of events in vac (per 100,000 person- days)
AF	-0.151	0.860	0.236	-0.642	5.21E-01	0.542	1.364	23	0.93	274	1.44
CAD	-0.574	0.563	0.155	-3.713	2.05E-04	0.416	0.762	61	2.48	443	2.33
COPD	-1.551	0.212	0.265	-5.85	4.92E-09	0.126	0.357	22	0.89	63	0.33
Dementia	-2.171	0.114	0.324	-6.69	2.24E-11	0.06	0.216	18	0.73	28	0.15
Heart Failure	-1.751	0.174	0.199	-8.803	1.34E-18	0.118	0.256	41	1.66	109	0.57
Non covid pneumonia	-2.226	0.108	0.151	-14.773	2.20E-49	0.08	0.145	91	3.70	139	0.73
Organ specific autoimmune	0.317	1.372	0.37	0.856	3.92E-01	0.665	2.833	9	0.37	125	0.66
Renal Failure	-0.879	0.415	0.249	-3.528	4.19E-04	0.255	0.677	28	1.14	112	0.59
Stroke	-1.724	0.178	0.172	-10.001	1.50E-23	0.127	0.25	54	2.19	173	0.91
Systemic autoimmune	-0.362	0.696	0.51	-0.709	4.78E-01	0.256	1.892	5	0.20	44	0.23
T2DM	-1.533	0.216	0.414	-3.704	2.12E-04	0.096	0.486	9	0.37	27	0.14
VTE	-0.853	0.426	0.233	-3.661	2.51E-04	0.27	0.673	30	1.22	135	0.71

Coef, coefficient from Cox regression; SE, standard error; HR, hazard ratio; LCI and UCI, lower and upper 95% confidence interval. AF, atrial fibrillation; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HTN, hypertension; Immunodeficiencies, disorders related to immunodeficiencies (details listed in supplementary tables); T2DM, type 2 diabetes; VTE, venous thromboembolism; vac, vaccinated group; unvac, unvaccinated group.

Results with $p < 0.05$ are in bold.

The results above were based on the ‘advanced model’ (i.e. consideration of all covariates with pre-screening). No further PERR or PTDM adjustments were made and for the vaccinated group day0 is the date of vaccination.

Table 2 Association of (at least one dose of) COVID-19 vaccination with hospitalization from various disorders after PERR (prior event rate ratio) adjustment

Outcome	beta-post	beta-pre	beta-diff	boot-se	HR	LCI	UCI	Z	P
AF	-0.151	0.199	-0.35	0.288	0.704	0.401	1.239	-1.217	2.24E-01
CAD	-0.574	0.085	-0.66	0.233	0.517	0.327	0.817	-2.827	4.70E-03
COPD	-1.551	-0.401	-1.15	0.423	0.317	0.138	0.726	-2.716	6.60E-03
Dementia	-2.171	-1.27	-0.9	0.416	0.406	0.18	0.919	-2.162	3.06E-02
Heart Failure	-1.751	-0.563	-1.188	0.271	0.305	0.179	0.519	-4.382	1.18E-05
HTN	0.363	0.103	0.261	3.158	1.298	0.003	633.389	0.083	9.34E-01
Non covid pneumonia	-2.226	-0.57	-1.656	0.223	0.191	0.123	0.295	-7.438	1.02E-13
Organ specific autoimmune	0.317	0.422	-0.106	1.688	0.9	0.033	24.621	-0.063	9.50E-01
Renal Failure	-0.879	-0.481	-0.397	0.416	0.672	0.297	1.52	-0.954	3.40E-01
Stroke	-1.724	-0.22	-1.503	0.276	0.222	0.13	0.382	-5.453	4.94E-08
Systemic autoimmune	-0.362	0.069	-0.43	2.423	0.65	0.006	75.146	-0.178	8.59E-01
T2DM	-1.533	-0.789	-0.745	1.31	0.475	0.036	6.189	-0.568	5.70E-01
VTE	-0.853	-0.422	-0.432	1.391	0.649	0.042	9.93	-0.31	7.56E-01

Please refer to relevant abbreviations of table 1. Results with $p < 0.05$ are in bold.

Beta-post, coefficient from Cox regression in the post-vaccination period; beta-pre, coefficient from Cox regression in the pre-vaccination period; beta-diff, difference in coefficients in the post- and pre-vaccination periods. The PERR approach adjusts for differences of the two groups prior to the introduction of vaccination, hence reducing unmeasured confounding.

1000 bootstraps were used to derive the standard error (boot-se) of beta-diff.

Table 3 Association of (at least one dose of) COVID-19 vaccination with hospitalization from various disorders with PTDM (prescription time distribution matching) adjustment

Outcome	Coef	Exp(coef) [HR]	Se(coef)	Z	P	LCI	UCI	No of Persons unvac	Rate of events in unvac (per 100,000 person- days)	No of Persons vac	Rate of events in vac (per 100,000 person- days)
AF	0.02	1.02	0.315	0.064	9.49E-01	0.55	1.892	11	0.90	274	1.44
CAD	-0.335	0.716	0.207	-1.617	1.06E-01	0.477	1.074	27	2.22	443	2.33
COPD	-0.044	0.957	0.601	-0.073	9.42E-01	0.295	3.109	3	0.25	63	0.33
Dementia	-1.702	0.182	0.473	-3.598	3.21E-04	0.072	0.461	6	0.49	28	0.15
Heart Failure	-1.745	0.175	0.251	-6.942	3.88E-12	0.107	0.286	21	1.73	109	0.57
HTN	0.423	1.527	0.732	0.579	5.63E-01	0.364	6.409	2	0.16	60	0.32
Non covid pneumonia	-1.846	0.158	0.2	-9.214	3.14E-20	0.107	0.234	36	2.96	139	0.73
Organ specific autoimmune	0.672	1.959	0.52	1.294	1.96E-01	0.707	5.426	4	0.33	125	0.66
Renal Failure	-0.126	0.881	0.38	-0.332	7.40E-01	0.419	1.856	10	0.82	112	0.59
Stroke	-1.259	0.284	0.242	-5.207	1.92E-07	0.177	0.456	21	1.73	173	0.91
Systemic autoimmune	0.775	2.17	1.025	0.756	4.50E-01	0.291	16.173	1	0.08	44	0.23
T2DM	-1.176	0.308	0.566	-2.078	3.77E-02	0.102	0.935	4	0.33	27	0.14
VTE	-0.562	0.57	0.304	-1.846	6.49E-02	0.314	1.035	13	1.07	135	0.71

Please refer to the legends of table 1.